Do analysts prefer HSCS or QTEX?

HeartSciences presently has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than QTREX Quantum. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 QTREX Quantum 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, HSCS or QTEX?

HeartSciences has higher earnings, but lower revenue than QTREX Quantum. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$9.14M -$3.22 N/A QTREX Quantum $290K 172.31 -$13.22M N/A N/A

Is HSCS or QTEX more profitable?

QTREX Quantum's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% QTREX Quantum N/A N/A N/A

Does the media refer more to HSCS or QTEX?

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. HeartSciences' average media sentiment score of 0.50 beat QTREX Quantum's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QTREX Quantum 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IINN or HSCS?

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, IINN or HSCS?

HeartSciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $289K 172.90 -$13.22M N/A N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is IINN or HSCS more profitable?

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Inspira Technologies OXY B.H.N. N/A N/A N/A HeartSciences N/A -816.90% -181.97%

Does the media favor IINN or HSCS?

In the previous week, Inspira Technologies OXY B.H.N. and Inspira Technologies OXY B.H.N. both had 1 articles in the media. HeartSciences' average media sentiment score of 0.50 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNXT or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% HeartSciences N/A -816.90% -181.97%

Does the media prefer RNXT or HSCS?

In the previous week, RenovoRx had 5 more articles in the media than HeartSciences. MarketBeat recorded 6 mentions for RenovoRx and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.50 beat RenovoRx's score of 0.34 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HSCS or MDAI more profitable?

HeartSciences has a net margin of 0.00% compared to Spectral AI's net margin of -69.27%. Spectral AI's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% Spectral AI -69.27% N/A -78.56%

Does the media prefer HSCS or MDAI?

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. Spectral AI's average media sentiment score of 0.67 beat HeartSciences' score of 0.50 indicating that Spectral AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spectral AI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HeartSciences (HSCS) Competitors

$3.06 -0.09 (-2.71%)

As of 01:37 PM Eastern

Compare

HSCS vs. QTEX, IINN, RNXT, COCH, and MDAI

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include Inspira Technologies OXY B.H.N. (QTEX), Inspira Technologies OXY B.H.N. (IINN), RenovoRx (RNXT), Envoy Medical (COCH), and Spectral AI (MDAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to QTREX Quantum?

HeartSciences (NASDAQ:HSCS) and QTREX Quantum (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

HeartSciences has higher earnings, but lower revenue than QTREX Quantum.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
QTREX Quantum	$290K	172.31	-$13.22M	N/A	N/A

QTREX Quantum's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
QTREX Quantum	N/A	N/A	N/A

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 12.7% of QTREX Quantum shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 29.4% of QTREX Quantum shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HeartSciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, QTREX Quantum has a beta of 4.23, indicating that its stock price is 323% more volatile than the broader market.

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. HeartSciences' average media sentiment score of 0.50 beat QTREX Quantum's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QTREX Quantum	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences presently has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than QTREX Quantum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
QTREX Quantum	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

HeartSciences beats QTREX Quantum on 6 of the 11 factors compared between the two stocks.

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, Inspira Technologies OXY B.H.N. and Inspira Technologies OXY B.H.N. both had 1 articles in the media. HeartSciences' average media sentiment score of 0.50 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289K	172.90	-$13.22M	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

HeartSciences beats Inspira Technologies OXY B.H.N. on 6 of the 11 factors compared between the two stocks.

How does HeartSciences compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, RenovoRx had 5 more articles in the media than HeartSciences. MarketBeat recorded 6 mentions for RenovoRx and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.50 beat RenovoRx's score of 0.34 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RenovoRx has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
HeartSciences	N/A	-816.90%	-181.97%

RenovoRx presently has a consensus price target of $8.50, suggesting a potential upside of 558.91%. HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 154.78%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	51.98	-$11.17M	-$0.31	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

RenovoRx beats HeartSciences on 10 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Envoy Medical?

HeartSciences (NASDAQ:HSCS) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

HeartSciences has higher earnings, but lower revenue than Envoy Medical. HeartSciences is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Envoy Medical	$240K	191.53	-$23.76M	-$0.76	N/A

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 7.2% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Envoy Medical	-11,304.83%	N/A	-144.13%

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 154.78%. Envoy Medical has a consensus target price of $2.17, suggesting a potential upside of 263.84%. Given Envoy Medical's stronger consensus rating and higher probable upside, analysts plainly believe Envoy Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

HeartSciences has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. HeartSciences' average media sentiment score of 0.50 beat Envoy Medical's score of -0.30 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Envoy Medical	Neutral

Summary

Envoy Medical beats HeartSciences on 9 of the 13 factors compared between the two stocks.

How does HeartSciences compare to Spectral AI?

HeartSciences (NASDAQ:HSCS) and Spectral AI (NASDAQ:MDAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 154.78%. Spectral AI has a consensus price target of $4.00, suggesting a potential upside of 177.78%. Given Spectral AI's stronger consensus rating and higher possible upside, analysts plainly believe Spectral AI is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, HeartSciences and HeartSciences both had 1 articles in the media. Spectral AI's average media sentiment score of 0.67 beat HeartSciences' score of 0.50 indicating that Spectral AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spectral AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by company insiders. Comparatively, 13.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HeartSciences has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Spectral AI has higher revenue and earnings than HeartSciences. Spectral AI is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Spectral AI	$19.65M	2.36	-$7.57M	-$0.35	N/A

HeartSciences has a net margin of 0.00% compared to Spectral AI's net margin of -69.27%. Spectral AI's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Spectral AI	-69.27%	N/A	-78.56%

Summary

Spectral AI beats HeartSciences on 11 of the 13 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.18M	$5.88B	$7.58B	$12.61B
Dividend Yield	N/A	1.71%	2.47%	45.15%
P/E Ratio	-0.95	26.63	275.74	25.71
Price / Sales	N/A	76.15	567.14	76.53
Price / Cash	N/A	32.95	27.10	37.77
Price / Book	43.64	5.85	10.49	5.76
Net Income	-$9.14M	$146.95M	$3.51B	$381.68M
7 Day Performance	-0.49%	0.08%	0.50%	-0.22%
1 Month Performance	-35.41%	-4.19%	-7.21%	-7.78%
1 Year Performance	-7.14%	4.14%	1.44%	-7.04%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.694 of 5 stars	$3.06 -2.7%	$8.00 +161.9%	-4.6%	$15.18M	N/A	N/A	14
QTEX Inspira Technologies OXY B.H.N.	1.1648 of 5 stars	$1.46 -7.6%	N/A	N/A	$56.80M	$290K	N/A	41	Gap Down
IINN Inspira Technologies OXY B.H.N.	N/A	$1.58 flat	N/A	+26.4%	$56.80M	$289K	N/A	20	High Trading Volume
RNXT RenovoRx	2.5726 of 5 stars	$1.12 -2.6%	$8.50 +658.9%	+9.3%	$51.90M	$1.12M	N/A	17	Analyst Downgrade
COCH Envoy Medical	2.7154 of 5 stars	$0.64 -3.4%	$2.17 +240.0%	-29.9%	$50.90M	$240K	N/A	47	Gap Down Trading Halted

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 10/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. QTEX, IINN, RNXT, COCH, and MDAI

How does HeartSciences compare to QTREX Quantum?

Summary

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Summary

How does HeartSciences compare to RenovoRx?

Summary

How does HeartSciences compare to Envoy Medical?

Summary

How does HeartSciences compare to Spectral AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. QTEX, IINN, RNXT, COCH, and MDAI

How does HeartSciences compare to QTREX Quantum?

Which has higher earnings and valuation, HSCS or QTEX?

Is HSCS or QTEX more profitable?

Do insiders & institutionals hold more shares of HSCS or QTEX?

Which has more risk and volatility, HSCS or QTEX?

Does the media refer more to HSCS or QTEX?

Do analysts prefer HSCS or QTEX?

Summary

How does HeartSciences compare to Inspira Technologies OXY B.H.N.?

Is IINN or HSCS more profitable?

Does the media favor IINN or HSCS?

Do insiders & institutionals have more ownership in IINN or HSCS?

Which has more risk & volatility, IINN or HSCS?

Do analysts rate IINN or HSCS?

Which has higher earnings & valuation, IINN or HSCS?

Summary

How does HeartSciences compare to RenovoRx?

Does the media prefer RNXT or HSCS?

Which has more volatility and risk, RNXT or HSCS?

Is RNXT or HSCS more profitable?

Do analysts recommend RNXT or HSCS?

Which has higher valuation and earnings, RNXT or HSCS?

Do institutionals & insiders hold more shares of RNXT or HSCS?

Summary

How does HeartSciences compare to Envoy Medical?

Which has preferable valuation and earnings, HSCS or COCH?

Do insiders & institutionals have more ownership in HSCS or COCH?

Is HSCS or COCH more profitable?

Do analysts rate HSCS or COCH?

Which has more volatility & risk, HSCS or COCH?

Does the media refer more to HSCS or COCH?

Summary

How does HeartSciences compare to Spectral AI?

Do analysts recommend HSCS or MDAI?

Does the media prefer HSCS or MDAI?

Do insiders & institutionals have more ownership in HSCS or MDAI?

Which has more volatility & risk, HSCS or MDAI?

Which has better valuation & earnings, HSCS or MDAI?

Is HSCS or MDAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools